CannEpilTM available for Australian supply under Authorised Prescriber Scheme
First commercial-scale production and material revenues to commence from MXC Investigational Medicinal Product (IMP)
• MXC’s Medicinal Cannabis based IMP, CannEpilTM is now available for supply in Australia under the Authorised Prescriber Scheme
• Authorisation has been granted by the TGA to specialist prescribers who are now authorised to supply CannEpilTM to patients in Australia
• Authorisation follows recent Human Research Ethics Committee endorsement from St Vincent’s Hospital Melbourne for the use of CannEpilTM in the treatment of adult patients with drug-resistant epilepsy
• Represents a major milestone for MXC, validating and confirming its seed-topharma strategy with the start of commercial supply of its first IMP offering
• The Company expects this to initially generate $1 million in annualised revenue from the initial base of approximately 100 patients
• CannEpilTM is expected to be available for supply in Australia by December 2018
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.